First-in-human trial launches focused ultrasound treatment for schizophrenia hallucinations
Source Summary
A first-in-human clinical trial has begun testing focused ultrasound as a treatment for auditory hallucinations in schizophrenia patients. Auditory hallucinations affect more than 70% of people with schizophrenia, and approximately 40% continue to experience persistent hallucinations despite antipsychotic medication treatment. The trial addresses an urgent clinical need for new therapeutic approaches for treatment-resistant cases.
Why it matters
This trial represents a potential new treatment pathway for the substantial portion of schizophrenia patients who do not respond adequately to existing antipsychotic medications.
